AACRpublished

Abstract CT087: Phase I/II FIH study of IPN60300, a first-in-class ADC targeting ITGA2, to assess the safety, tolerability, PK, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumors

AACR published a clinical-trial abstract describing the ongoing Phase I/II first-in-human study of IPN60300, a first-in-class ADC targeting ITGA2, in adults with locally advanced solid tumors.

2026-04-17 Foreseen Biotechnology Public article URL ready for sharing

AACR Journals published Abstract CT087 in Cancer Research, describing a Phase I/II first-in-human study of IPN60300, a first-in-class antibody-drug conjugate targeting ITGA2.

The abstract record covers the study design to assess safety, tolerability, pharmacokinetics, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumors.

Source: Cancer Research / AACR Journals. DOI: https://doi.org/10.1158/1538-7445.AM2026-CT087.

Source

https://aacrjournals.org/cancerres/article/86/8_Supplement/CT087/783046/Abstract-CT087-Phase-I-II-FIH-study-of-IPN60300-a

Collaboration & media inquiries

For additional information about the platform, pipeline or partnership opportunities, submit an inquiry through the contact page.

Contact Foreseen